(R)-Equol 是一种 ERα (Ki:27.4 nM) 和 Erβ (Ki:15.4 nM) 激动剂。

(R)-Equol is an ERα and ERβ agonist with Kis of 27.4 and 15.4 nM, respectively.

(R)-Equol produced a dose-dependent inhibitory effect on the invasive ability of MDA-MB-231 cells, and this inhibitory effect was obvious at the highest test concentration (50 μM).Following 48-h exposure to (R)-Equol, invasion is reduced by 62% (p=0.009, versus untreated cells) with 50 μM (R)-Equol. Matrix metalloproteinase-2 (MMP-2) expression is significantly down-regulated following treatment with 50 μM (R)-Equol (p=0.035) [2].

In Animals, (R)-Equol has a significantly reduced number of palpable tumors over time when compared with Controls (P=0.002).In addition, the number of palpable tumors formed by each rat in the (R)-Equol fed group was significantly lower than that of rats treated with S-(-)equol (P = 0.008). (R)-Equol-fed animals have 43% fewer tumors than the control group and this difference is highly statistically significant (P=0.004). The number of tumors/tumor-bearing animals is significantly lower in the animals fed (R)-Equol compare with Controls (3.3±0.4 versus 5.5±0.5, P=0.004). At necropsy, the mean (±SEM) tumor weight per animal for (R)-Equol fed rats (5.3±1.1 mg) is significantly reduced (P=0.04) when compared with Controls (9.9±1.4 mg). Feeding the (R)-Equol diet results in significantly increased tumor latency (P=0.003) [3].

221054-79-1

C15H14O3

242.27

(+)-Equol;R-雌马酚

DMSO:100 mg/mL (412.76 mM),Need ultrasonic and warming
Powder: -20°C for 3 years
In solvent: -80°C for 2 years